有機(jī)陰離子轉(zhuǎn)運(yùn)多肽1B1（OATP1B1）是一種負(fù)責(zé)轉(zhuǎn)運(yùn)多種內(nèi)外源性物質(zhì)進(jìn)入肝細(xì)胞發(fā)揮作用的攝入型轉(zhuǎn)運(yùn)蛋白。他汀類藥物又稱3-羥基-3-甲基戊二酸單酰輔酶A（HMG-CoA）還原酶抑制劑，臨床上廣泛應(yīng)用于調(diào)脂及心腦血管疾病的預(yù)防，其療效及不良反應(yīng)有顯著的個(gè)體化差異。研究表明OATP1B1基因多態(tài)性是導(dǎo)致他汀類藥物個(gè)體化差異的重要因素。對(duì)OATP1B1基因多態(tài)性對(duì)他汀類藥物影響的研究進(jìn)展進(jìn)行綜述，為他汀類藥物的個(gè)體化、安全化應(yīng)用提供可能的理論指導(dǎo)。

OATP1B1 is a kind of uptake transporter which is responsible for transporting a variety of endogenous and exogenous substances into hepatocytes. Statins, also known as 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors, are widely used in the prevention of lipid-lowering and cardiovascular and cerebrovascular diseases, with significant individual differences in efficacy and adverse reactions. Studies have shown that the OATP1B1 gene polymorphism is an important factor leading to individual differences in statins. The research progress on effect of OATP1B1 gene polymorphism on statins is reviewed in this article and to provide possible theoretical guidance for the individual and safe application of statins.

R973